Namita Roy-Chowdhury Selected Research

Crigler-Najjar Syndrome

1/2019	Genes and Pathways Promoting Long-Term Liver Repopulation by Ex Vivo hYAP-ERT2 Transduced Hepatocytes and Treatment of Jaundice in Gunn Rats.
1/2017	Gunn Rats as a Surrogate Model for Evaluation of Hepatocyte Transplantation-Based Therapies of Crigler-Najjar Syndrome Type 1.
7/2015	Amelioration of Hyperbilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes.
9/2009	Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Namita Roy-Chowdhury Research Topics

Disease

8	Liver Diseases (Liver Disease) 01/2019 - 08/2002
4	Crigler-Najjar Syndrome 01/2019 - 09/2009
4	Hyperbilirubinemia 03/2017 - 01/2012
3	Infections 12/2016 - 01/2003
2	End Stage Liver Disease 01/2019 - 01/2017
2	Nephrocalcinosis 05/2008 - 11/2006
2	Primary Hyperoxaluria (Oxaluria, Primary) 05/2008 - 11/2006
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Atherosclerosis 01/2019
1	Atherosclerotic Plaque (Atheroma) 01/2019
1	Carcinogenesis 01/2019
1	Substance-Related Disorders (Drug Abuse) 03/2017
1	Metabolic Diseases (Metabolic Disease) 01/2017
1	Brain Injuries (Brain Injury) 07/2015
1	Pulmonary Emphysema 05/2011
1	Emphysema 05/2011
1	Neoplasms (Cancer) 11/2009
1	Weight Loss (Weight Reduction) 11/2009
1	Diarrhea 11/2009
1	Kernicterus 04/2009
1	Gilbert Disease 04/2009
1	Hyperoxaluria (Oxaluria) 05/2008
1	Liver Failure 03/2007
1	Rare Diseases (Rare Disease) 11/2006
1	Renal Insufficiency (Renal Failure) 11/2006
1	Crystalluria 11/2006
1	Urinary Calculi (Urinary Calculus) 11/2006
1	Hepatitis 01/2003

Drug/Important Bio-Agent (IBA)

4	BilirubinIBA 03/2017 - 04/2009
2	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 01/2019 - 04/2009
2	Proteins (Proteins, Gene)FDA Link 05/2011 - 11/2006
2	OxalatesIBA 05/2008 - 11/2006
2	Alanine-glyoxylate transaminase (alanine-glyoxylate aminotransferase)IBA 05/2008 - 11/2006
2	Ethylene Glycol (Monoethylene Glycol)IBA 05/2008 - 11/2006
1	CholesterolIBA 01/2019
1	ApolipoproteinsIBA 01/2019
1	Apolipoproteins E (ApoE)IBA 01/2019
1	LigandsIBA 01/2019
1	Estrogen ReceptorsIBA 01/2019
1	LDL Receptors (LDL Receptor)IBA 01/2019
1	Tamoxifen FDA LinkGeneric 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019
1	Atazanavir Sulfate (Reyataz)FDA Link 03/2017
1	Pharmaceutical PreparationsIBA 03/2017
1	EBV-encoded nuclear antigen 1IBA 12/2016
1	Protease Inhibitors (Protease Inhibitor)IBA 05/2011
1	ElectrolytesIBA 11/2009
1	Uridine Diphosphate (UDP)IBA 04/2009
1	glucose-6-phosphate dehydrogenase A-IBA 04/2009
1	EnzymesIBA 04/2009
1	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 04/2009
1	glyoxylic acid (glyoxylate)IBA 11/2006
1	Calcium OxalateIBA 11/2006
1	TransferasesIBA 11/2006
1	Alanine (L-Alanine)FDA Link 11/2006
1	EpitopesIBA 01/2003

Therapy/Procedure

9	Transplantation 01/2019 - 08/2002
5	Liver Transplantation 01/2019 - 11/2006
5	Therapeutics 01/2019 - 01/2003
1	Cell Transplantation 01/2019
1	Intravenous Injections 09/2009